1. Agin MA, Kazierad DJ, Abel R, Anziano R, Billing CB, Layton G, Mancuso J, Strieter D, Xu W, Blum RA, Jorkasky DK (2003) Assessing QT variability in healthy volunteers. J Clin Pharmacol 43:1028, Abstract #61
2. Arsenic trioxide (Trisenox®) Prescribing Information. http://www.trisenox.com/hcp/trisenox-prescribing-information.pdf
3. Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609–3615
4. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN (2001) The QT interval. Prog Cardiovasc Dis 43(5 suppl 1):1–45
5. Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L (2009) Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib. Clin Cancer Res 15:7045–7052